Safely accelerating drug development for brighter outcomes

Significance of the topic

Analytical spectroscopy, materials characterization and controlled extrusion technologies are central to modern pharmaceutical development. They enable robust target characterization, formulation optimization, process analytical technology (PAT), and regulatory-compliant quality assurance from early discovery through industrial-scale manufacturing. Integrating instrumentation, secure data software, and lifecycle service reduces risk, shortens time-to-market, and helps ensure patient safety and consistent product performance.

Objectives and overview of the document

This document presents a consolidated portfolio of spectroscopy and materials-characterization tools, extrusion platforms, software for data security and regulatory compliance, and global service offerings tailored for pharmaceutical workflows. It maps capabilities to the four principal phases of drug development (Research & Discovery, Development, Clinical Study, Manufacturing), highlights unique instrument features, and describes scale-up strategies and support services that facilitate reproducible product development and compliant release.

Methodology and workflow

The recommended analytical workflow is organized into four stages:

• Research & Discovery: target validation, lead selection, initial feasibility — techniques include LC-MS, FTIR, Raman, UV-Vis, XRD, micro UV and small-scale extrusion for formulation feasibility.
• Development: pilot-scale formulation optimization, polymorph control, compounding and scale-up — use HME/TSG extrusion, NIR/Raman for PAT, FTIR and XRD for solid-state characterization.
• Clinical Study: manufacture of clinical batches and process verification — apply twin-screw extrusion for formulation scale-up and PAT for in-process control.
• Manufacturing: industrial-scale production, continuous processes, QA/QC — implement inline NIR, automated Raman/FTIR, XRD for polymorphism/amorphous content, UV-Vis for potency and purity checks.

The approach emphasizes non-destructive, fast spectroscopic assays and inline monitoring to reduce sampling, enable faster decision-making, and support continuous manufacturing strategies.

Instrumentation used

The portfolio spans complementary techniques and specified platforms with validated software options for regulated environments:

• Spectroscopy: FTIR (Nicolet Summit series with OMNIC Paradigm), Raman (benchtop and microscopy systems), NIR (process and at-line probes), UV-Vis (Evolution 350, NanoDrop One, micro UV).
• X-ray methods: XRD (ARL EQUINOX series with SolstiX XRD Software and Security Suite), surface & elemental analysis (XPS, EDS).
• Materials characterization: rheometers/viscometers for rheological profiling; IR microscopy and surface probes for packaging and coating analysis.
• Extrusion and granulation: Pharma mini HME (micro-compounding, feasibility), Pharma 11/16/24 twin-screw extruders for laboratory, pilot and production scales supporting hot-melt extrusion (HME) and twin-screw granulation (TSG).
• Software and compliance: Thermo Scientific Security Suite, OMNIC Paradigm, ValPro package and SolstiX — provide audit trails, validated configurations and 21 CFR Part 11, USP and EP compatibility.
• Service & support: global installation, IQ/OQ/PQ qualification assistance, digital remote support, training, maintenance and tailored service contracts.

Key instrument attributes include pharma-grade construction, interchangeable screw designs for HME/TSG, throughput ranges from gram-scale micro-compounds to multi-kg/h production, and software enabling validated QA/QC workflows.

Main results and discussion

As a comprehensive solution, the combined instrumentation and software offer:

• Reliable, reproducible analytical performance across the lifecycle — enabling consistent API dispersion, controlled polymorphism, and confirmed amorphous versus crystalline content.
• Real-time process monitoring (NIR, Raman) and PAT integration with HME/TSG to reduce offline testing, shorten cycle times and improve batch-to-batch consistency.
• Validated data integrity pathways (Security Suite, OMNIC Paradigm, ValPro) that address 21 CFR Part 11 and pharmacopeial requirements for QA/QC and regulatory submission.
• Scalable extrusion solutions from feasibility to manufacturing, minimizing reformulation risk during scale-up and facilitating continuous manufacturing implementations.
• Comprehensive service infrastructure to maintain uptime, support qualification and provide application-specific training that improves analytical readiness for audits.

Discussion points emphasize the value of combining orthogonal techniques (e.g., Raman + FTIR + XRD) for robust solid-state and composition analysis, and employing inline analytics to manage process variability and material heterogeneity during compounding and extrusion.

Benefits and practical applications

Primary practical benefits and use cases include:

• Raw material identification and contamination screening using FTIR and XRD.
• Formulation optimization and solubility enhancement via hot-melt extrusion (HME).
• Inline PAT for process control and continuous manufacturing using NIR and Raman.
• Polymorphism assessment, amorphous fraction quantification and stability testing with XRD and Raman.
• Microvolume concentration/purity checks with micro UV-Vis systems to reduce sample handling and dilution steps.
• Rheological characterization to inform extrusion parameters and predict processing behavior.
• Regulatory-compliant data collection, audit trails and validated analytical methods for GMP and submission dossiers.

Future trends and opportunities

Key future directions and opportunities highlighted by the portfolio and industry context include:

• Wider adoption of continuous manufacturing and real-time release testing, underpinned by integrated PAT sensors and control strategies.
• Greater digitalization: unified security frameworks, cloud-enabled data management (with validated controls), and linking analytics to laboratory informatics and MES.
• Advanced data analytics and machine learning applied to multivariate spectral data for predictive process control and early anomaly detection.
• Miniaturization and increased throughput for early feasibility (micro-compounding) to accelerate lead triage with minimal material consumption.
• Enhanced remote services, predictive maintenance and augmented-support tools to maximize uptime and reduce operational risk.

Conclusion

The integrated offering of spectroscopy, X-ray and materials characterization, extrusion platforms, validated software and global service provision forms an end-to-end toolkit for pharmaceutical development. By enabling robust solid-state characterization, inline PAT, scalable extrusion and validated data integrity, the suite supports faster development cycles, improved product quality and regulatory compliance from discovery through commercial manufacturing.

Reference

Listed resources and technical literature provided by the vendor and referenced in the source material (company as author):

• Thermo Fisher Scientific. At-line and in-process monitoring in pharmaceutical manufacturing. 2021.
• Thermo Fisher Scientific. Discovery to QC resource center. 2021.
• Thermo Fisher Scientific. Drug formulation and manufacturing resource page. 2021.
• Thermo Fisher Scientific. UV-Vis Testing Solutions for Pharmaceuticals; Micro UV-Vis resource; Precision performance for advanced analysis. 2021.
• Thermo Fisher Scientific. Nicolet Summit integrated computer; Security and compliance resources for Nicolet Summit FTIR and OMNIC Paradigm. 2021.
• Thermo Fisher Scientific. Case studies and application notes: FT-NIR for melt extrusion monitoring; Raman analysis of transdermal patches; XRD studies of pharmaceutical products; Raman imaging of hot-melt extrusions; FT-Raman mapping of solid dosage forms; Guide to pharmaceutical standards for UV-Vis; Rheology and extrusion solutions; Pharma mini Implant Line. 2021.